Real-World Evidence of Brodalumab Effectiveness for the Treatment of Psoriasis.

Brodalumab is a recombinant, fully human monoclonal antibody antagonist of the human interleukin-17 (IL-17) receptor A. It is indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Brodalumab blocks signaling mediated by IL-17 cytokines, disrupting the inflammatory feedback loop between immune cells and keratinocytes that drives psoriasis, which may explain its efficacy in clinical trials. To explore its postapproval effectiveness, this review synthesizes real-world evidence of brodalumab across 14 international studies. Studies showed rapid onset of action and sustained effectiveness through extended follow-up periods. Notably, brodalumab achieved high response rates in patients whose psoriasis had failed to respond to prior IL-17A inhibitors. Comparative analyses position brodalumab favorably against other biologics, demonstrating its superior response rates and faster onset of action. Furthermore, brodalumab was efficacious in difficult-to-treat psoriasis manifestations, including nail psoriasis, generalized pustular psoriasis, and psoriatic erythroderma. Limitations of this report include variations in study designs, follow-up durations, and baseline characteristics across reviewed studies. The evidence collectively establishes brodalumab as a valuable therapeutic option, particularly for patients with treatment-resistant psoriasis and challenging subtypes. &nbsp.